Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794587 | 1.00 | LMNA (0.48) | LMNASLC18A3FUCA1ALDH1A1TSHR | |
| SCHEMBL13229594 | 0.86 | L3MBTL1 (0.51) | SLC18A3FUCA1ALDH1A1TSHRMAPK1 | |
| SCHEMBL2847210 | 0.86 | L3MBTL1 (0.51) | SLC18A3FUCA1ALDH1A1TSHRMAPK1 | |
| SCHEMBL14385505 | 0.85 | SLC18A3 (0.55) | SLC18A3FUCA1ALDH1A1 | |
| SCHEMBL4083554 | 0.83 | LMNA (0.60) | LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL9643788 | 0.83 | LMNA (0.60) | LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL13229733 | 0.82 | SLC18A3 (0.57) | SLC18A3FUCA1ALDH1A1 | |
| SCHEMBL2794440 | 0.82 | SLC18A3 (0.57) | SLC18A3FUCA1ALDH1A1 | |
| SCHEMBL2792852 | 0.82 | FUCA1 (0.63) | SLC18A3FUCA1ALDH1A1 | |
| SCHEMBL13229582 | 0.82 | FUCA1 (0.63) | SLC18A3FUCA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DE DR. ESTEVE, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DE DR. ESTEVE, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| EP-1849781-A1 | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PAH, HMBS, P4HA1 | LMNA 2201/4885SLC18A3 1740/4885FUCA1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.